This lecture discusses alternative strategies for spinal muscular atrophy (SMA) gene therapy, including the use of antisense oligonucleotides to inhibit exon 8 splicing, enhancing exon 8 inclusion to improve exon 7 levels, and exploring genome editing through homology-directed repair of the SMN2 gene. The potential of non-homologous repair and the limitations of the CRISPR-Cas9 system in SMA gene therapy are also addressed.